V-11-0711 

V-11-0711 is a potent and selective Chk-α (IC₅₀ = 20 nM) inhibitor. V-11-0711 can significantly reduce PCho levels. V-11-0711 causes a reversible growth arrest. V-11-0711 induces apoptosis at high concentrations. V-11-0711 can be used for the study of cervical cancer and triple-negative breast cancer^[1][2].

V-11-0711 (0.1-10 μM, 48 h) reduces PC and GPC levels in MDA-MB-231 cells and SUM149 cells^[2].
V-11-0711 (0.1-10 μM, 48 h) does not reduce Chk-α protein levels in SUM149 cells at low doses, but reduces Chk-α protein levels by approximately 50% at high doses^[2].
V-11-0711 (0.1-10 μM, 48 h) significantly reduces the level of PtdCho in SUM149 cells, and increases fatty acid levels at 10 μM^[2].
V-11-0711 (0.1-10 μM, 48 h) increases the number of lipid droplets in SUM149 cells by approximately 1.8 times at 10 μM^[2].
V-11-0711 (0.1-10 μM, 48 h) induces apoptosis in SUM149 cells at 10 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

421.57

C₂₇H₃₅NO₃

1428339-47-2

Solid

White to off-white

O[C@@]([C@]1([H])C2CCN(CC2)C1)(C3=CC=CC=C3)CCC4=C(C=CC=C4)OC5CCOCC5

Room temperature in continental US; may vary elsewhere.

• [1]. Falcon SC, et al. A non-catalytic role of choline kinase alpha is important in promoting cancer cell survival. Oncogenesis. 2013;2(3):e38.  [Content Brief]

  [2]. Mori N, et al. Choline kinase-α protein and phosphatidylcholine but not phosphocholine are required for breast cancer cell survival. NMR Biomed. 2015 Dec;28(12):1697-706.  [Content Brief]